BACKGROUND: @entity288 have been a mainstay of rejection prophylaxis for several decades, despite the multiple adverse effects of long-term use, including @entity1017 , @entity407 , @entity6 , @entity101 , and @entity79 . The detrimental effect of @entity230 on the metabolic profile begins in the early posttransplantation period, and the complete avoidance of @entity230 in transplantation would therefore be optimal. We hypothesized that the addition of @entity618 ( @entity2098 ) and a humanized monoclonal anti- @entity2902 antibody (daclizumab) to a @entity205 (CsA microemulsion)-based immunosuppression protocol would permit transplantation without @entity230 . METHODS: @entity134 -free renal transplantation was attempted in 57 @entity1 treated with daclizumab, @entity2098 , and CsA. Twenty-eight @entity1 received kidneys from living donors; the remaining 29 received cadaveric grafts. RESULTS: At 1 year, @entity1 and graft survival were 95% and 89%, respectively. Fourteen @entity1 (25%) experienced rejections, of which 13 were readily reversed with @entity230 ; 1 @entity1 required OKT3. Mean serum @entity1011 at 12 months for @entity1 not experiencing rejection was 149+/-58 micromol/L, compared with 158+/-102 micromol/L for those experiencing rejection. Five @entity1 required hospitalization for @entity281 ; no @entity1 developed @entity1071 . At baseline, 17 @entity1 required 3 or more antihypertensive medications, compared with 2 @entity1 at 1 year. Three of 43 @entity7964 @entity1 developed @entity6 during the study. There was no significant reduction in lumbar or femoral bone density. CONCLUSIONS: On the basis of these positive results, we believe @entity134 avoidance with this immunosuppressive regimen merits further study.

A pilot study of XXXX -free immunosuppression in the prevention of acute rejection in renal allograft recipients.

@entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['lymphoproliferative disease'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity7964 :: ('OMIM:612551', 'Disease') :: ['nondiabetic'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disease'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['Steroid', 'steroid'] @entity2902 :: ('3559', 'Gene') :: ['CD25'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['Corticosteroids']
@entity134 :: (CHEBI:35341,Chemical) :: ['steroid']
